Amgen: Repatha to Be Available Only at Lower List Price Next Year

Date : 10/24/2019 @ 1:53PM
Source : Dow Jones News
Stock : Amgen Inc (AMGN)
Quote : 241.49  0.99 (0.41%) @ 12:59AM
After Hours
Last Trade
Last $ 241.49 ◊ 0.00 (0.00%)

Amgen: Repatha to Be Available Only at Lower List Price Next Year

Historical Stock Chart

3 Months : From Oct 2019 to Jan 2020

Click Here for more Amgen Charts.

By Colin Kellaher


Amgen Inc. (AMGN) Thursday said Repatha will only be available at its lower list price next year as the company works to make the cholesterol drug more affordable.

Amgen last year cut the list price of Repatha by 60% to $5,850 a year in a bid to reduce out-of-pocket costs, especially for Medicare patients.

The Thousand Oaks, Calif., biotechnology company also continued to offer the original list price option of more than $14,000 to minimize disruption in the supply chain and allow time for payers and pharmacy benefit managers to modify existing contracts.

Amgen, which reported $91 million in U.S. Repatha sales for the second quarter, said it will discontinue the Repatha original list price option Dec. 31.


Write to Colin Kellaher at


(END) Dow Jones Newswires

October 24, 2019 09:38 ET (13:38 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest AMGN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.